Nationwide Children’s Hospital Research Institute

Abeona Therapeutics receives FDA Orphan Drug Designations for Sanfilippo

Wednesday, May 14, 2014

Abeona Therapeutics, a start-up company created around intellectual property licensed from Nationwide Children’s Hospital to develop treatments for Sanfilippo Syndrome Types A and B, has been granted Orphan Drug Designations for its lead investigational therapies by the FDA Office of Orphan Products Development. Following the successful close of seed financing in late 2013, Abeona is raising funds to advance its gene therapy-based clinical programs for both Sanfilippo Syndrome type A and B. Phase I/II clinical trials for both diseases are anticipated to begin in 2014.

[Read More]

DIA names Barbara Lopez Kunz global chief executive

Thursday, August 1, 2013

DIA, a neutral, global, professional member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related healthcare products, has named Barbara Lopez Kunz global chief executive, to lead the organization beginning in September. Kunz brings worldwide leadership experience to DIA as former president of the global health and life sciences business at Battelle, an international science and technology nonprofit organization that explores emerging areas of science, develops and commercializes technology and manages laboratories.

[Read More]